The identification of potent and selective imidazole-based inhibitors of B-Raf kinase

  • Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81. doi: 10.1016/j.bmcl.2005.09.072.
Andrew K Takle  1 ,  Murray J B Brown ,  Susannah Davies ,  David K Dean ,  Gerraint Francis ,  Alessandra Gaiba ,  Alex W Hird ,  Frank D King ,  Peter J Lovell ,  Antoinette Naylor ,  Alastair D Reith ,  Jon G Steadman ,  David M Wilson
Affiliations
  • 1. Department of Medicinal Chemistry, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK. [email protected]
PMID: 16260133 DOI: 10.1016/j.bmcl.2005.09.072
Abstract

A novel triarylimidazole derivative, SB-590885 (33), bearing a 2,3-dihydro-1H-inden-1-one oxime substituent has been identified as a potent and extremely selective inhibitor of B-Raf kinase.

Products